Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | PTGFR | P43088 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112460 | 0.87 | ACHE (0.52) | AURKALMNAHTTSMN1; SMN2BCHE | |
| Hydrochloric Acid SCHEMBL3118517 | 0.86 | LMNA (0.52) | EGFRERBB2AURKALMNAHTT | |
| SCHEMBL3108332 | 0.76 | MEN1 (0.54) | EGFRLMNAHTTSMN1; SMN2PDE5A | |
| SCHEMBL20327097 | 0.75 | APP (0.57) | EGFRLMNAHTTSMN1; SMN2PDE5A | |
| SCHEMBL3109780 | 0.74 | PDGFRB (0.43) | EGFRHTTPTGFR | |
| SCHEMBL3109770 | 0.74 | PTGFR (0.41) | SMN1; SMN2PTGFR | |
| SCHEMBL3121533 | 0.74 | ACHE (0.51) | EGFRERBB2AURKALMNASMN1; SMN2 | |
| SCHEMBL3118614 | 0.74 | ACHE (0.53) | AURKALMNABCHEACHEAPP | |
| SCHEMBL3107574 | 0.73 | PDE5A (0.52) | HTTSMN1; SMN2CHRM4PDE5AMEN1 | |
| SCHEMBL21514373 | 0.73 | KRAS (0.55) | EGFRERBB2LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | EGFR 3147/4885ERBB2 2818/4885AURKA 1394/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2648/4885ERBB2 2343/4885AURKA 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.